✦ LIBER ✦

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

✍ Scribed by Edward J. Gane; Regine Rouzier; Catherine Stedman; Alicja Wiercinska-Drapalo; Andrzej Horban; Linda Chang; Ying Zhang; Pratibha Sampeur; Isabel Nájera; Patrick Smith; Nancy S. Shulman; Jonathan Q. Tran

Book ID: 116652418
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 988 KB
Volume: 55
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2011.01.046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Partial splenic embolization and peg-IFN

Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcome

✍ Rafael Bárcena; Ana Moreno; José R Foruny; Javier Blázquez; Javier Graus; José M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Detection and biological activity of the

Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients

✍ Zahra Alvandi; Lisette Provacia; Byron E.E. Martina; Albert D.M.E. Osterhaus; Ba 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

O.091 Early prediction of response to Pe

O.091 Early prediction of response to Peg-IFNα-2a or Peg-IFNα-2b plus ribavirin in the single chronic hepatitis C patients by modeling the dynamics of infected cells

✍ P. Ciccorossi; P. Colombatto; A. Maina; L. Civitano; F. Oliveri; R. Sacco; B. Co 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Pharmacokinetics and response of obese p

Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN α-2a (40KD) (PEGASYS®)

✍ Brian Bressler; Ka Wang; Joseph F. Grippo; E. Jenny Heathcote 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 639 KB

Pegylated interferon alpha-2b (Peg-IFN α

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

✍ T. Oze; N. Hiramatsu; T. Yakushijin; M. Kurokawa; T. Igura; K. Mochizuki; K. Ima 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

18 A phase 2 study to assess antiviral r

18 A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albuferon™ in IFN-α NA1VE subjects with genotype 1 chronic hepatitis C

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB